Patents by Inventor Weiting ZHONG

Weiting ZHONG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2,4,6-tri-substituted pyrimidine compounds as ATR kinase inhibitors
    Patent number: 12692257
    Abstract: Provided are compounds represented by general formula (I), which can be used for treating ATR kinase-mediated diseases, such as proliferative diseases, such as cancer. Further provided are a pharmaceutical composition of the compound represented by general formula (I), a use thereof in treating ATR kinase-mediated diseases, and a preparation thereof.
    Type: Grant
    Filed: May 20, 2021
    Date of Patent: July 28, 2026
    Assignee: BEIJING TIDE PHARMACEUTICAL CO., LTD.
    Inventors: Yanping Zhao, Bin Liu, Yuanyuan Jiang, Weiting Zhong, Huifen Xu, Hongjun Wang, Li Mao, Jingtao Li, Honglei Zhang, Chuangchuang Huang, Jing Li, Jing Zhao, Weina Liu, Nana Tian, Liying Zhou, Yanan Liu
  • PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR
    Publication number: 20260184717
    Abstract: Disclosed is a compound of a general formula (I), which may be used for the treatment of ATR kinase-mediated diseases, for example, proliferative diseases such as cancer. Further disclosed are a preparation method for the compound of the general formula (I), a pharmaceutical composition, and use of the pharmaceutical composition for the treatment of ATR kinase-mediated diseases.
    Type: Application
    Filed: February 18, 2026
    Publication date: July 2, 2026
    Inventors: Cheung Ling Cheng, Yanping Zhao, Hongjun Wang, Bin Liu, Weiting Zhong, Huifen Xu, Chuangchuang Huang, Jing Li, Weina Liu
  • METHOD FOR TREATING PNEUMOCONIOSIS
    Publication number: 20260137682
    Abstract: Provided is a method for preventing, relieving, alleviating and/or treating pneumoconiosis, the method comprising administering to an individual in need thereof an effective amount of the compound of formula (I) or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate. N-oxide, isotope-labeled compound, metabolite or prodrug thereof.
    Type: Application
    Filed: October 12, 2023
    Publication date: May 21, 2026
    Inventors: Hongjun WANG, Weiting ZHONG, Jing LI, Weina LIU, Jing ZHAO, Yanping ZHAO
  • Pyrazolopyrimidine compound used as ATR kinase inhibitor
    Patent number: 12595263
    Abstract: Disclosed is a compound of a general formula (I), which may be used for the treatment of ATR kinase-mediated diseases, for example, proliferative diseases such as cancer. Further disclosed are a preparation method for the compound of the general formula (I), a pharmaceutical composition, and use of the pharmaceutical composition for the treatment of ATR kinase-mediated diseases.
    Type: Grant
    Filed: July 13, 2021
    Date of Patent: April 7, 2026
    Assignee: BEIJING TIDE PHARMACEUTICAL CO., LTD.
    Inventors: Cheung Ling Cheng, Yanping Zhao, Hongjun Wang, Bin Liu, Weiting Zhong, Huifen Xu, Chuangchuang Huang, Jing Li, Weina Liu
  • Method for treating idiopathic pulmonary fibrosis
    Patent number: 12582653
    Abstract: A method for preventing, alleviating and/or treating idiopathic pulmonary fibrosis, which comprises administering an effective amount of a compound represented by formula (I), or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof to an individual in need thereof.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: March 24, 2026
    Assignee: BEIJING TIDE PHARMACEUTICAL CO., LTD.
    Inventors: Yanping Zhao, Hongjun Wang, Yuanyuan Jiang, Weiting Zhong, Jing Zhao, Jing Li, Weina Liu, Liying Zhou, Yanan Liu
  • 2, 4, 6-tri-substituted pyrimidine compound as ATR kinase inhibitor
    Patent number: 12544382
    Abstract: Compounds of general formula (A) can be used for treating ATR kinase-mediated diseases, for example, hyperplastic diseases such as cancers.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: February 10, 2026
    Assignee: BEIJING TIDE PHARMACEUTICAL CO., LTD.
    Inventors: Yanping Zhao, Hongjun Wang, Bin Liu, Yuanyuan Jiang, Weiting Zhong, Huifen Xu, Honglei Zhang, Chuangchuang Huang, Nana Tian, Jing Zhao, Jing Li, Weina Liu, Liying Zhou, Yanan Liu
  • Method for treating fatty liver disease and/or steatohepatitis
    Patent number: 12485108
    Abstract: The present invention falls within the field of biological medicine, and specifically relates to a method for preventing, alleviating and/or treating fatty liver disease and/or steatohepatitis. The method comprises administering, to an individual in need thereof, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, an ester, a stereoisomer, a polymorph, a solvate, an N-oxide, an isotopically labeled compound, a metabolite or a prodrug thereof.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: December 2, 2025
    Assignee: BEIJING TIDE PHARMACEUTICAL CO., LTD.
    Inventors: Yuanyuan Jiang, Weiting Zhong, Yanping Zhao, Hongjun Wang, Jing Zhao, Jing Li, Weina Liu, Liying Zhou, Yanan Liu
  • Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and use thereof
    Patent number: 12398118
    Abstract: A Rho-associated protein kinase (ROCK) inhibitor represented by formula (I), a pharmaceutical composition comprising same, and a use thereof for preventing or treating ROCK-mediated diseases.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: August 26, 2025
    Assignee: BEIJING TIDE PHARMACEUTICAL CO., LTD.
    Inventors: Yanping Zhao, Hongjun Wang, Gong Li, Yuanyuan Jiang, Xiang Li, Bin Liu, Kai Liu, Weiting Zhong, Fajie Li, Jing Zhao, Jianmei Pang, Liying Zhou
  • Double-stranded RNA molecule targeting CKIP-1 and use thereof
    Patent number: 11939578
    Abstract: The present invention relates to the field of biomedicine, particularly to double-stranded RNA molecules targeting CKIP-1 and uses thereof, particularly to use of the double-stranded RNA molecules for the treatment of inflammatory diseases such as arthritis, particularly rheumatoid arthritis.
    Type: Grant
    Filed: September 14, 2021
    Date of Patent: March 26, 2024
    Assignee: BEIJING TIDE PHARMACEUTICAL CO., LTD.
    Inventors: Yanping Zhao, Hongjun Wang, Yuanyuan Jiang, Weiting Zhong, Jianmei Pang, Gong Li, Xiang Li, Yixin He, Liying Zhou, Yanan Liu
  • METHOD FOR TREATING GRAFT VERSUS HOST DISEASE CAUSED BY HEMATOPOIETIC STEM CELL TRANSPLANTATION
    Publication number: 20230285393
    Abstract: A method for preventing, alleviating and/or treating graft versus host disease caused by hematopoietic stem cell transplantation, which comprises administering an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof to an individual in need thereof.
    Type: Application
    Filed: July 21, 2021
    Publication date: September 14, 2023
    Inventors: Cheung Ling CHENG, Yanping ZHAO, Hongjun WANG, Weiting ZHONG, Jing LI, Jing ZHAO, Weina LIU
  • PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR
    Publication number: 20230271968
    Abstract: Disclosed is a compound of a general formula (I), which may be used for the treatment of ATR kinase-mediated diseases, for example, proliferative diseases such as cancer. Further disclosed are a preparation method for the compound of the general formula (I), a pharmaceutical composition, and use of the pharmaceutical composition for the treatment of ATR kinase-mediated diseases.
    Type: Application
    Filed: July 13, 2021
    Publication date: August 31, 2023
    Inventors: Cheung Ling Cheng, Yanping Zhao, Hongjun Wang, Bin Liu, Weiting Zhong, Huifen Xu, Chuangchuang Huang, Jing Li, Weina Liu
  • 2,4,6-TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AS ATR KINASE INHIBITORS
    Publication number: 20230212160
    Abstract: Provided are compounds represented by general formula (I), which can be used for treating ATR kinase-mediated diseases, such as proliferative diseases, such as cancer. Further provided are a pharmaceutical composition of the compound represented by general formula (I), a use thereof in treating ATR kinase-mediated diseases, and a preparation thereof.
    Type: Application
    Filed: May 20, 2021
    Publication date: July 6, 2023
    Inventors: Yanping Zhao, Bin Liu, Yuanyuan Jiang, Weiting Zhong, Huifen Xu, Hongjun Wang, Li Mao, Jingtao Li, Honglei Zhang, Chuangchuang Huang, Jing .. Li, Jing Zhao, Weina Liu, Nana Tian, Liying Zhou, Yanan Liu
  • RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20230030115
    Abstract: The present invention relates to a Rho-associated protein kinase inhibitor of formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and a use of the same in preventing or treating a disease mediated by Rho-associated protein kinase (ROCK).
    Type: Application
    Filed: July 6, 2021
    Publication date: February 2, 2023
    Inventors: Yanping ZHAO, Hongjun WANG, Gong LI, Yuanyuan JIANG, Xiang LI, Bin LIU, Weiting ZHONG, Kai LIU, Fajie LI, Liying ZHOU, Yanan LIU
  • METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS
    Publication number: 20220378743
    Abstract: The present invention falls within the field of biological medicine, and specifically relates to a method for preventing, alleviating and/or treating fatty liver disease and/or steatohepatitis. The method comprises administering, to an individual in need thereof, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, an ester, a stereoisomer, a polymorph, a solvate, an N-oxide, an isotopically labeled compound, a metabolite or a prodrug thereof.
    Type: Application
    Filed: February 26, 2020
    Publication date: December 1, 2022
    Applicant: BEIJING TIDE PHARMACEUTICAL CO., LTD.
    Inventors: Yuanyuan JIANG, Weiting ZHONG, Yanping ZHAO, Hongjun WANG, Jing ZHAO, Jing Li, Weina LIU, Liying ZHOU, Yanan LIU
  • 2, 4, 6-TRI-SUBSTITUTED PYRIMIDINE COMPOUND AS ATR KINASE INHIBITOR
    Publication number: 20220378799
    Abstract: Compounds of general formula (A) can be used for treating ATR kinase-mediated diseases, for example, hyperplastic diseases such as cancers. Also provided are a pharmaceutical composition of the compounds of general formula (A), a use of the pharmaceutical composition for treating the ATR kinase-mediated diseases and a preparation method for the pharmaceutical composition.
    Type: Application
    Filed: June 5, 2020
    Publication date: December 1, 2022
    Inventors: Yanping Zhao, Hongjun Wang, Bin Liu, Yuanyuan Jiang, Weiting Zhong, Huifen Xu, Honglei Zhang, Chuangchuang Huang, Nana Tian, Jing Zhao, Jing Li, Weina Liu, Liying Zhou, Yanan Liu
  • METHOD FOR TREATING IDIOPATHIC PULMONARY FIBROSIS
    Publication number: 20220233538
    Abstract: A method for preventing, alleviating and/or treating idiopathic pulmonary fibrosis, which comprises administering an effective amount of a compound represented by formula (I), or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof to an individual in need thereof.
    Type: Application
    Filed: June 24, 2020
    Publication date: July 28, 2022
    Inventors: Yanping ZHAO, Hongjun WANG, Yuanyuan JIANG, Weiting ZHONG, Jing ZHAO, Jing LI, Weina LIU, Liying ZHOU, Yanan LIU
  • Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
    Patent number: 11390609
    Abstract: The present invention relates to a Rho-associated protein kinase inhibitor of formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and a use of the same in preventing or treating a disease mediated by Rho-associated protein kinase (ROCK).
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: July 19, 2022
    Assignee: BEIJING TIDE PHARMACEUTICAL CO., LTD.
    Inventors: Yanping Zhao, Hongjun Wang, Gong Li, Yuanyuan Jiang, Xiang Li, Bin Liu, Weiting Zhong, Kai Liu, Fajie Li, Liying Zhou, Yanan Liu
  • Double-stranded RNA Molecule Targeting CKIP-1 and Use Thereof
    Publication number: 20220064645
    Abstract: The present invention relates to the field of biomedicine, particularly to double-stranded RNA molecules targeting CKIP-1 and uses thereof, particularly to use of the double-stranded RNA molecules for the treatment of inflammatory diseases such as arthritis, particularly rheumatoid arthritis.
    Type: Application
    Filed: September 14, 2021
    Publication date: March 3, 2022
    Inventors: Yanping ZHAO, Hongjun WANG, Yuanyuan JIANG, Weiting ZHONG, Jianmei PANG, Gong LI, Xiang LI, Yixin HE, Liying ZHOU, Yanan LIU
  • RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF
    Publication number: 20220002266
    Abstract: A Rho-associated protein kinase (ROCK) inhibitor represented by formula (I), a pharmaceutical composition comprising same, and a use thereof for preventing or treating ROCK-mediated diseases.
    Type: Application
    Filed: November 8, 2019
    Publication date: January 6, 2022
    Inventors: Yanping ZHAO, Hongjun WANG, Gong LI, Yuanyuan JIANG, Xiang LI, Bin LIU, Kai LIU, Weiting ZHONG, Fajie LI, Jing ZHAO, Jianmei PANG, Liying ZHOU
  • Double-stranded RNA molecule targeting CKIP-1 and use thereof
    Patent number: 11155819
    Abstract: The present invention relates to the field of biomedicine, particularly to double-stranded RNA molecules targeting CKIP-1 and uses thereof, particularly to use of the double-stranded RNA molecules for the treatment of inflammatory diseases such as arthritis, particularly rheumatoid arthritis.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: October 26, 2021
    Assignee: BEIJING TIDE PHARMACEUTICAL CO., LTD.
    Inventors: Yanping Zhao, Hongjun Wang, Yuanyuan Jiang, Weiting Zhong, Jianmei Pang, Gong Li, Xiang Li, Yixin He, Liying Zhou, Yanan Liu